Biocon Biologics, a subsidiary of Biocon has signed a distribution agreement with Sandoz, granting the company exclusive rights to promote, sell and distribute `Adalimumab BS for subcutaneous injection [FKB]’* in Japan. Based on this, Viatris has completed marketing and promotion of the product as of December 15, but will continue to provide transition support until Sandoz will gradually assume responsibilities for the product starting February 15, 2024, a company statement said.
Business News: Latest News on Business, Stock Markets, Financial News, India Business & World Business News